Central Admixture Pharmacy Services, Inc., Allentown, PA

Is Central Admixture Pharmacy Services, Inc. an FDA-registered 503B outsourcing facility?

Yes. FDA’s registered outsourcing facility list, updated Nov 6, 2026, names Central Admixture Pharmacy Services, Inc. in Allentown, PA, first registered Feb 28, 2014 and most recently registered Nov 21, 2025. FDA lists its last inspection as Sep 5, 2025, with a Form FDA 483 issued; FDA lists the action on that inspection as “Regulatory Meeting Held 5/5/2026”.

FDA registers outsourcing facilities under section 503B; state boards of pharmacy issue pharmacy licenses separately. FDA’s list does not say which drugs a facility makes.

Location on FDA’s list
Allentown, PA
Initial registration
Feb 28, 2014
Most recent registration
Nov 21, 2025
Last inspection
Sep 5, 2025
Form 483 issued at last inspection
Yes
Recall after last inspection
No
Action on last inspection
Regulatory Meeting Held 5/5/2026
Intends to compound sterile drugs from bulk substances
Yes

FDA inspections and actions on record

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this facility as Central Admixture Pharmacy Services, Inc. (CAPS), Allentown, PA, a 503B facility, with 5 listed actions, including 2 Form 483s, 1 warning letter and 1 warning letter close-out (2020 to 2025).

Document
Sep 5, 2025Amended Form 483Amended 483 Issued 09/05/2025fda.gov
Mar 29, 2024Warning letterWarning Letter Issued 03/29/2024FDA copy (archived)
Mar 30, 2023Form 483483 Issued 03/30/2023FDA copy (archived)
Jun 17, 2020FMD-145 letterFMD-145 Letter Issued 06/17/2020FDA copy (archived)
Jun 17, 2020Warning letter close-outWarning Letter Closeout Issued 06/17/2020Not linked by FDA

A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own. An untitled or FMD-145 letter states FDA’s view when it was issued.

Matched to the 503B list by city, state and the exact legal name with the same legal ending. Check the heading above against the facility you are looking for.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Central Admixture Pharmacy Services, Inc., Allentown, PA (FEI number 3009590582), matched to this page by exact name, city and state. It lists 5 inspections: 4 OAI, 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Sep 5, 2025Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30095905821285946
Mar 30, 2023Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30095905821201784
Aug 22, 2018Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30095905821063439
Feb 11, 2015Official Action Indicated (OAI)Drug Quality Assurance (Drugs)3009590582914112
Jun 11, 2014Official Action Indicated (OAI)Drug Quality Assurance (Drugs)3009590582883358

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483s for this site have 13 numbered observations in all, across 3 inspections ending Sep 19, 2016 to Sep 5, 2025. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Aug 18, 2025 to Sep 5, 2025: 5 observations

Firm on the cover
Central Admixture Pharmacy Services, Inc., DDRESS 6580 Snowdrift Rd Ste 100, Allentown, PA 18106-9331
FEI number
3009590582
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
US Customhouse Rrn900 200 Chestnut St Philadelphia, PA 19106
Matched to this page by
FEI number on the cover; linked from actions page, 503B list, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not followed.

Specifically,

A. Your firm discontinued use of the <Redacted B4> system in May 2025, which previously provided continuous non-viable particulate monitoring within ISO Class 5, 7, and 8 areas. Since discontinuation, over <Redacted B4> batches have been manufactured using, <Redacted B4> the <Redacted B4> particle counter as an alternative. Per SOP-CAPS-4000582, the <Redacted B4> collects only <Redacted B4> non-viable particulate samples per session, providing intennittent rather than continuous monitoring in ISO 5 areas where sterile drug products are compounded.

B. Per SOP-CAPS-4000710, each of the <Redacted B4> ISO 7 compounding conidors is monitored only <Redacted B4> for viable and non-viable particulates, despite active use across <Redacted B4>. Since Januaiy 2024, <Redacted B4> alarm and action level excursions for viable CFU recoveries have been documented across ISO 7 air, surface, and personnel monitoring samples.

Observation 2

AMENDM ENT 1

Specifically,

A. The firm failed to demonstrate reproducibility of the <Redacted B4> Microbial Detection System used for sterility testing of drug products compounded in IV bags. The firm <Redacted B4> Microbial Detection System Results Data from <Redacted B4> Microbial Detection System Performance Qualification (PQ) for Sterility Testing of <Redacted B4> Products Summary Report" #V0184 was generated by testing drug product in the presence of ATCC organisms. This performance qualification was done with <Redacted B4> samples from <Redacted B4> in <Redacted B4> by the same analyst on the same day with the same microbial preparation. This validation was performed by and approved by your Quality Validation Manager on 10/18/2019. Additionally, the environmental isolate used as representative flora during the method validation was an environmental isolate from the <Redacted B4> in <Redacted B4> not the actual 503B production sites in Allentown, PA.

B. The <Redacted B4> Microbial Detection System is designed to warn the user of microbial growth via the generation of <Redacted B4> as a biproduct of microbial metabolism. ...

Read the full 483 (PDF on fda.gov)

Observation 3

Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications prior to release.

Specifically,

Your firm's 100% visual inspection process is deficient. Since August 2024, there have been approximatebly 94 cases of first Acceptable Quality Level (AQL) failures, primarily for particulates <Redacted B4> and leaking bags <Redacted B4> and seven second AQL failures involving compounded aseptically filled products. The detection of visible particulate matter and leaking containers following your I00% visual inspection demonstrates that the inspection program does not consistently detect product defects prior to release.

Observation 4

Reports of analysis from component suppliers are accepted in lieu of testing each component for conformity with all appropriate written specifications, without performing at least one specific identity test on each component and establishing the reliability of the supplier's analyses through appropriate validation of the supplier's test results at appropriate intervals.

Specifically,

Incoming components and drug product containers used in drug products compounded for intravenous administration ai·e not tested or inspected. Materials are accepted based on the suppliers certificate of analysis, without sampling and examination. Examples of materials used without appropriate evaluation include empty and filled diluent bags used as final product containers for compounded IV drug products, including but not limited to the products listed in the table below.

AM ENDMENT 1

include empty and filled diluent bags used as final product containers for compounded IV drng products, including but not limited to the products listed in the table below. ...

Read the full 483 (PDF on fda.gov)

Observation 5

There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.

Specifically,

Your procedure SOP-CAPS-4000582 "Environmental Monitoring-503B" allows for non-viable particulate (NVP) sample retesting without investigation following alert or action level excursions in ISO 5, 7, and 8 areas. Specifically, Section 6.10.4.A states that no investigation is required if <Redacted B4> NVP samples collected after an alert or action alarm fall below the excursion threshold at the same location.

Since January 2025, your firm has documented 8 instances of NVP excursion events where no investigations were initiated, instead relying on this retesting protocol. When questioned, your firm explained that this resampling practice provides "a more representative snapshot of the environment."

This practice allows potentially significant environmental excursions to go uninvestigated by using retesting to override initial alert and action level results.

THIS OBSERVATION WAS PREVIOUSLY CITED IN 2023

AM ENDMENT 1

Inspection Feb 27, 2023 to Mar 30, 2023: 6 observations

Firm on the cover
Central Admixture Pharmacy Services, Inc., 6580 Snowdrift Rd Ste 100, Allentown, PA 18106-9331
FEI number
3009590582
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
US Customhouse Rrn 900 200 Chestnut St Philadelphia, PA 19106
Matched to this page by
FEI number on the cover; linked from Data Dashboard, actions page
FDA document
Read the full 483 (PDF on fda.gov); FDA also posts it as https://web.archive.org/web/20250506103522/https://www.fda.gov/media/170878/download

Observation 1

There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.

Specifically, your firm's investigation into mold and spore-forming micro-organisms identified from environmental monitoring (EM) samples collected in ISO 5 classified clean room areas used in the production of sterile drug products are deficient:

A. Investigation NQE-US58-221214-564 was opened 12/14/2022 and closed 03/27/2023 for all mold recoveries during the month of November 2022. In November 2022, your firm had five EM excursions of 1 CFU/mL (specification: <Redacted B4> CFU) identified as Penicillium chrysogenum/ Penicillium species recovered in four different ISO 5 laminar air flow (LAF) hoods. Your firm released two out of <Redacted B4> of the affected lots in which 1 CFU of Penicillium chrysogenum was recovered in <Redacted B4> different ISO 5 EM surface samples of LAF hoods <Redacted B4>: Potassium Phosphate 30mmol/500mL NS, Lot <Redacted B4>, Exp: 16 Feb 2023 and del Nido formula (Plasmalyte), Lot# <Redacted B4> Exp: 16 Jan 2023. ...

Read the full 483 (PDF on fda.gov)

Observation 2

Written records of investigations into unexplained discrepancies and the failure of a batch or any of its components to meet specifications do not always include the conclusions and follow-up.

Specifically, your firm's environmental monitoring (EM) and personnel monitoring (PM) data shows recovery of spore forming microorganisms of 1 CFU/mL in your ISO 5 critical zone areas for approximately 100 instances since November 2022 to March 2023. Despite recovering a significant number of bacteria, yeast, mold, and other spore forming organisms, your firm failed to conduct investigations into the root causes or implement adequate collective and preventative actions to mitigate the risk of mold and spore forming bacteria thereafter. During this same time frame, your firm continued to manufacture and distribute sterile injectable drug products made in the same ISO 5 locations with recovery of micro-organisms. The following are some examples of the drug product(s) batches produced on the same days mold forming bacteria was recovered from their respective ISO 5 areas: ...

Read the full 483 (PDF on fda.gov)

Observation 3

Laboratory controls do not include the establishment of scientifically sound and appropriate sampling plans and test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality and purity.

Specifically,

A. According to your firm's procedure, TP-CAPS-4000040, Sterilty (testing Using <Redacted B4>), step 2.6.3A states to collect a <Redacted B4> aliquot to test the sterility of your sterile drug products using an alternative sterility test method via the <Redacted B4>. Your firm lacks supporting data or scientific rationale demonstrating that a reduced sample volume relative to the volume recommended in USP<71> is at least equivalent to the USP method, For example, for your firm's drug product, Oxytocin 30 units/ 500mL NS, Lot <Redacted B4> , Exp: 01 May 2023, only <Redacted B4> was tested from each of the containers collected, which is only <Redacted B4> of your fill volume. Your firm provided no data to support the adequacy of conducting sterility testing with sample size volumes that are less than those required by the USP <71> sterility testing method. ...

Read the full 483 (PDF on fda.gov)

Observation 4

Each batch of drug product purporting to be sterile is not laboratory tested to determine conformance to such requirements.

Specifically, there is no scientific rationale or data to support the use of a reduced sample size of <Redacted B4> used by your firm in the alternate sterility testing system, <Redacted B4>, which has a maximum sample size capacity of <Redacted B4>. For example, the firm's sterihty test sample size 4 for the total parenteral nutrition (TPN) product, Trophamine 2% / Dextrose 10% product filled to <Redacted B4>, is <Redacted B4> of the product volume, which is tested for sterility using the <Redacted B4>. However, USP <71> requires a minimum sample size of 10% of the total volume <Redacted B4> for the TPN example). Your firm uses this <Redacted B4> sterility test method to conduct sterility testing on all finished sterile injectable products produced and distributed and this observation impacts all lots of sterile drug product currently released and within expiry.

THIS OBSERVATION WAS PREVIOUSLY CITED IN 2015 AND 2018.

Observation 5

Procedures designed to prevent objectionable Inicroorganisms in drug products not required to be sterile are not established and followed.

Specifically,

A. On 03/01/2023, during the production of Micro Del Nido, L.ot <Redacted B4> Exp: 16 Apr ·7 2023, which was performed in the vertical Laminar Air Flow (LAF) hood <Redacted B4> was used to fill approximately <Redacted B4> syringes. During the production process, I observed an employee block the critical areas from receiving first pass air flow from the <Redacted B4> ISO 5 LAF hood when connecting and removing the syringes from the product <Redacted B4>. The operator was also observed inventing the syringe filled with sterile Micro Del Nido, Lot# <Redacted B4> , pointing the open end straight down which blocked first pass ISO 5 air to cap the filled syringe.

B. On 02/28/2023, during the filling process of Sodium Phosphate Lot <Redacted B4> Exp: 29 May 2023, your quality control technician was observed performing a finger-tip PM sample on an IV technician immediately after the IV technician sprayed their gloved hands with sterile <Redacted B4> while producing drug product in the ISO 5 LAF hood.

Observation 6

Appropriate controls are not exercised over computers or related systems to assure that changes in master production and control records or other records are instituted only by authorized personnel.

Specifically, on 03/01/2023, I observed that a quality control chemist was able to change the time, time zone and date and save these changes on the Ultra Performance Liquid Chromatography (UPLC) systems which is used to determined potency. The time, time zone, and date for your firm's <Redacted B4> )(<UPLC systems can be changed by the user with no requirement of administrative privileges thereby allowing for the altering of real-time records and data collection. Controls are not established to prevent changes to the set the time, date, and time zone of the UPLC systems.

Inspection Aug 29, 2016 to Sep 19, 2016: 2 observations

Firm on the cover
Central Admixt ure Pharmacy Servi ces, 6580 Snowdrift Rd St e 100 Inc . Producer of Sterile Drugs, Allent own, PA 18106- 9331 Producer of St erile Drugs
FEI number
3009590582
FDA district office on the cover
Philadelphia, PA 19106
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

There is a failure to thoroughly review any 1.mexplained discrepancy whether or not the batch has been already distributed.

Specifically,

Your deviation investigation #37-160203-009 regarding microbial organisms isolated in your cleanroom environment between January 2016 and August 2016 is deficient in that:

A) The microbial contamination discovered as part of the environmental monitoring (EM) conducted on 01/18/ 16 on the REDACTED (b)(4) for the micro-organism Phoma Spp., was not addressed as part of the investigation.

On 01/18/16, REDACTED (b)(4) used in the production of REDACTED (b)(4) units of Total Parenteral Nutrition (TPN) sterile The majority of these products are intended for use in neonatal intensive care unit (NICU) patients.

At the time of this event, your process for sterility testing of TPN products consisted of collecting REDACTED (b)(4) of the components used in the production of TPN products.

There were two other instances of microbial contamination found in cleanroom ISO Class 5 areas during environmental monitoring samples collected on 04/20/16 REDACTED (b)(4) and 06/23/16 ...

Read the full 483 (PDF on fda.gov)

Observation 2

Procedures describing the warehousing of drug products are not followed.

Specifically,

Your investigation for deviation #37-160203-009 indicates that as a result of the microbial contamination discovered during environmental monitoring conducted on 06/23116 on REDACTED (b)(4), lot #37-204337 and 37-204363 of Oxytocin 30 units/500mL NS were destroyed.

A review of the batch records for these lots found that after being released for distribution on 06/29/16, the status of the lots was never changed to "rejected".

The rejection log section of the batch records indicates the batches were "expired" on 08/31/16.

The destruction log indicates that the batches were destroyed because they were "expired".

There is no record documenting that the batches were quarantined as a result of this investigation.

Linked 483s whose text is not shown

GLP-1 records in this index

No FDA warning letter or recall report naming a GLP-1 drug in this index, as of Nov 15, 2026, is addressed to this facility’s exact legal name (Central Admixture Pharmacy Services, Inc.). That is not a finding beyond this index’s search.

The Central Admixture Pharmacy Services, Inc. pharmacy page answers whether it has had a state board action or FDA letter, from the same FDA lists.

FDA’s 503B list also names Central Admixture Pharmacy Services, Phoenix, AZ. Each is a separate listing with its own records; a similar name does not show they are the same firm.

This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.